Explore Zymeworks' Upcoming Investor Conferences
Zymeworks Inc. is excited to participate in several important investor conferences, showcasing its commitment to innovation in biotechnology. This Vancouver-based company specializes in developing novel biotherapeutics aimed at addressing challenging medical conditions, including cancer and autoimmune diseases.
Stifel Healthcare Conference Participation
During the Stifel Healthcare Conference, Zymeworks’ management team will engage in one-on-one meetings to share insights regarding their advancements and upcoming projects. This conference is scheduled for November 11, 2025, and will take place in New York City. Zymeworks is enthusiastic about connecting with investors who share their vision for pioneering healthcare solutions.
Jefferies London Healthcare Conference Attendance
Following the Stifel event, Zymeworks will also participate in the Jefferies London Healthcare Conference from November 17 to 19, 2025. This conference is another opportunity for Zymeworks to discuss its innovative pipeline of biotherapeutics and engage with international investors. These meetings are crucial for the company to highlight their ongoing projects and strategic direction.
About Zymeworks Inc.
Zymeworks Inc. is a dynamic clinical-stage biotechnology firm recognized for its unique approach to developing multifaceted biotherapeutics that can specifically target difficult conditions like cancer, inflammation, and autoimmune disorders. With a dedication to making a significant impact on patients' lives, Zymeworks strives to maximize the efficacy and impact of healthcare solutions.
Innovative Therapeutic Platforms
The company is particularly proud of its proprietary Azymetric™ technology, which led to the creation of zanidatamab, a bispecific antibody targeting HER2. This groundbreaking treatment has received multiple key approvals, marking it as a significant advancement in the treatment landscape for patients with HER2-positive biliary tract cancer. Zanidatamab's ability to dual-target HER2 puts Zymeworks at the forefront of targeted cancer therapies.
Robust Pipeline and Future Plans
Zymeworks continues to build a strong pipeline of wholly-owned product candidates, focusing on innovative antibody drug conjugates and multispecific antibody therapeutics. The company is currently recruiting participants for a Phase 1 study on ZW191, and ZW251 is anticipated to enter clinical trials shortly. These advancements underscore Zymeworks’ commitment to leading-edge biotechnology and addressing unmet medical needs effectively.
Collaborative Partnerships
In addition to developing internal therapies, Zymeworks has forged strategic partnerships with various biopharmaceutical companies, enhancing its ability to innovate and expand its therapeutic offerings. These collaborations are essential to leverage their platforms and bring transformative treatments to market.
Contact Information for Inquiries
For those interested in learning more about Zymeworks' initiatives and strategies, the company encourages inquiries:
Investor inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
Frequently Asked Questions
What is the primary focus of Zymeworks Inc.?
Zymeworks Inc. specializes in developing innovative biotherapeutics for difficult-to-treat diseases, including cancer and autoimmune disorders.
What upcoming conferences will Zymeworks participate in?
Zymeworks will participate in the Stifel Healthcare Conference and the Jefferies London Healthcare Conference in November 2025.
What is zanidatamab?
Zanidatamab is a HER2-targeted bispecific antibody developed by Zymeworks, recently approved for treating HER2-positive biliary tract cancer.
How is Zymeworks advancing its product pipeline?
The company is actively recruiting for clinical trials and continues to explore new therapeutic candidates to address unmet medical needs.
What partnerships does Zymeworks have?
Zymeworks collaborates with global biopharmaceutical companies to enhance its research and development efforts for biotherapeutics.
